Literature DB >> 20354817

The value of COX-2 expression in the prognostic parameters of invasive ductal carcinoma of the breast.

Nagehan Ozdemir Barısık1, Sevinc Hallac Keser, Aylin Ege Gul, Sibel Sensu, Nilufer Onak Kandemir, Hasan Fehmi Kucuk, Mahmut Gumus, Nimet Karadayı.   

Abstract

Cyclooxygenase is an enzyme that changes the immune response to malign cells and catalyzes prostaglandins that may have an impact on cell proliferation. The purpose of this study was to examine the relation between established clinicopathological parameters in breast carcinomas and COX-2 protein expression. COX-2, estrogen receptor (ER), progesterone receptor (PR) and c-erB-2 primary antibodies were assessed in the slides prepared from the paraffin blocks of 62 invasive ductal carcinoma cases. The relation between ER, PR, and c-erbB-2 positivity, histological grade, nuclear grade, lymphovascular invasion, tumor diameter, lymph node positivity, metastasis, and age were evaluated. The results were analyzed statistically. Cytoplasmic COX-2 expression was seen in 75.8% of all breast carcinomas. In both univariate and multivariate logistic regression analysis, there was a positive correlation between COX-2 expression and negative ER status, respectively (P=0.0173) (P=0.016). There was any statistically significant relation between PR positivity, c-erbB-2 positivity, histological grade, nuclear grade, lymphovascular invasion, tumor diameter, lymph node positivity, metastasis, and age (P≥0.05). Given that there was found a statistically significant relation between COX-2 expression and negative ER status, which is considered a poor prognostic parameter, suggests that COX-2 expression can have a place among the other prognostic parameters of breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20354817     DOI: 10.1007/s12032-010-9503-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  27 in total

1.  Expression of cyclooxygenase-2 and 12-lipoxygenase in human breast cancer and their relationship with HER-2/neu and hormonal receptors: impact on prognosis and therapy.

Authors:  A M Mohammad; H A Abdel; W Abdel; A M Ahmed; T Wael; G Eiman
Journal:  Indian J Cancer       Date:  2006 Oct-Dec       Impact factor: 1.224

2.  COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features.

Authors:  G Perrone; D Santini; B Vincenzi; M Zagami; A La Cesa; A Bianchi; V Altomare; A Primavera; C Battista; A Vetrani; G Tonini; C Rabitti
Journal:  Histopathology       Date:  2005-05       Impact factor: 5.087

3.  Additive effects of Cox-1 and Cox-2 inhibition on breast cancer in vitro.

Authors:  David W McFadden; Dale R Riggs; Barbara J Jackson; Cynthia Cunningham
Journal:  Int J Oncol       Date:  2006-10       Impact factor: 5.650

Review 4.  Cyclooxygenase-2: a target for the prevention and treatment of breast cancer.

Authors:  L R Howe; K Subbaramaiah; A M Brown; A J Dannenberg
Journal:  Endocr Relat Cancer       Date:  2001-06       Impact factor: 5.678

5.  HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice.

Authors:  Louise R Howe; Sung-Hee Chang; Kelly C Tolle; Rachelle Dillon; Lawrence J T Young; Robert D Cardiff; Robert A Newman; Peiying Yang; Howard T Thaler; William J Muller; Clifford Hudis; Anthony M C Brown; Timothy Hla; Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

6.  The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.

Authors:  Cornelia Leo; Stefanie Faber; Bettina Hentschel; Michael Höckel; Lars-Christian Horn
Journal:  Ann Diagn Pathol       Date:  2006-12       Impact factor: 2.090

7.  Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma.

Authors:  Carsten Denkert; Klaus-Jürgen Winzer; Berit-Maria Müller; Wilko Weichert; Sören Pest; Martin Köbel; Glen Kristiansen; Angela Reles; Antje Siegert; Hans Guski; Steffen Hauptmann
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

8.  Technique for the primary culture of human breast cancer cells and measurement of their prostaglandin secretion.

Authors:  J Watson; S Y Chuah
Journal:  Clin Sci (Lond)       Date:  1992-09       Impact factor: 6.124

9.  COX-2 expression in invasive breast cancer: correlation with prognostic parameters and outcome.

Authors:  Aziza Nassar; Anu Radhakrishnan; Isabel A Cabrero; George Cotsonis; Cynthia Cohen
Journal:  Appl Immunohistochem Mol Morphol       Date:  2007-09

10.  Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence.

Authors:  N Barnes; P Haywood; P Flint; W F Knox; N J Bundred
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

View more
  7 in total

1.  Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.

Authors:  Na Li; Huanhuan Li; Fan Su; Jing Li; Xiaoping Ma; Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.

Authors:  Huanhuan Li; Yuli Wang; Fan Su; Jing Li; Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 3.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

4.  Fatty acid metabolites in rapidly proliferating breast cancer.

Authors:  Joseph T O'Flaherty; Rhonda E Wooten; Michael P Samuel; Michael J Thomas; Edward A Levine; L Douglas Case; Steven A Akman; Iris J Edwards
Journal:  PLoS One       Date:  2013-05-02       Impact factor: 3.240

5.  Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma.

Authors:  M J D Prins; R J J Verhage; F J W ten Kate; R van Hillegersberg
Journal:  J Gastrointest Surg       Date:  2012-01-19       Impact factor: 3.452

6.  Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.

Authors:  Feng Xu; Mengxin Li; Chao Zhang; Jianxiu Cui; Jun Liu; Jie Li; Hongchuan Jiang
Journal:  Oncotarget       Date:  2017-01-24

7.  COX-2 expression in ovarian cancer: an updated meta-analysis.

Authors:  Haiming Sun; Xuelong Zhang; Donglin Sun; Xueyuan Jia; Lidan Xu; Yuandong Qiao; Yan Jin
Journal:  Oncotarget       Date:  2017-10-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.